2025. Evaluation of the CRISPR/Cas9 system as genome editing platform for the Mucopolysaccharidosis IV A using a strategy for induction of higher homologous recombination frequency. Universitas Scientiarum. 30, (Apr. 2025), 82–106. DOI:https://doi.org/10.11144/.